Skip to main content
Narimon Honarpour, MD, Cardiology, Los Angeles, CA

NarimonHonarpourMD

Cardiology Los Angeles, CA

Adult Congenital Heart Disease

Physician

Are you Dr. Honarpour?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 38 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    Ucla Med Cardio
    Box 951679, Bh-307 Chs
    Los Angeles, CA 90095
    Phone+1 310-825-5280

Summary

  • Dr. Narimon Honarpour, MD is a cardiologist in Los Angeles, California. He is currently licensed to practice medicine in California.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Cardiovascular Disease, 2005 - 2010
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2003 - 2006
  • University of Texas Southwestern Medical School
    University of Texas Southwestern Medical SchoolClass of 2003

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2005 - 2024

Publications & Presentations

PubMed

Authored Content

  • Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
  • Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
  • Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
  • Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
  • Join now to see all

Press Mentions

  • GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease
    GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual DiseaseJanuary 11th, 2021

Professional Memberships